Table 1.
Baseline characteristics of participants in the sildenafil and placebo treatment arms.
| All randomized subjects | Subjects with complete data for 6 months |
|||
|---|---|---|---|---|
| Sildenafil (n=10) |
Placebo (n=10) |
Sildenafil (n=7) |
Placebo (n=8) |
|
| Age (years) | 25.5 (8.2) | 22.6 (4.4) | 26.9 (9.5) | 23.4 (4.7) |
| Diagnosis | ||||
| Duchenne | 9 (90%) | 9 (90%) | 6 (86%) | 7 (88%) |
| Becker | 1 (10%) | 1 (10%) | 1 (14%) | 1 (13%) |
| Ethnic Group | ||||
| Caucasian | 7 (70%) | 8 (80%) | 4 (57%) | 7 (88%) |
| Asian | 1 (10%) | 2 (20%) | 1 (14%) | 1 (13%) |
| African American | 2 (20%) | 0 (0%) | 2 (29%) | 0 (0%) |
| Height (cm) | 160 (13) | 162 (15) | 162 (13) | 160 (16) |
| Weight (kg) | 69 (21.8) | 66.3 (20) | 76.1 (21.6) | 65.0 (18.5) |
| Systolic blood pressure (mmHg) | 110 (17) | 115 (16) | 117 (15) | 116 (15) |
| Diastolic blood pressure (mmHg) | 68 (13) | 69 (10) | 71 (14) | 67 (8) |
| Heart rate (bpm) | 80 (16) | 88 (11) | 85 (15) | 89 (12) |
| Ejection fraction (%) | 40.8 (8.9) | 43.9 (7.7) | 41.8 (9.6) | 45.3 (7.2) |
| Left ventricular end-systolic volume (ml) | 99.8 (55.3) | 86.7 (31.9) | 105.2 (63.8) | 84 (32.9) |
| ACE inhibitor or ARB | 10 (100%) | 10 (100%) | 7 (100%) | 8 (100%) |
| Beta blocker | 7 (70%) | 4 (40%) | 5 (71%) | 3 (38%) |
| Digoxin | 3 (30%) | 1 (10%) | 2 (29%) | 1 (13%) |
| Diuretics | 2 (20%) | 3 (30%) | 1 (14%) | 2 (25%) |
| Mechanical Ventilation | 2 (20%) | 2 (20%) | 1 (14%) | 2 (25%) |
| Non-invasive Ventilation | 6 (60%) | 3 (30%) | 4 (57%) | 1 (13%) |
Data are mean (SD) or n (%).